IL6 and rheumatoid arthritis: Besides directly IL-6 targeting agents, Janus kinase inhibitors reduce IL-6 signaling, and they may have impressive SAA-reducing effects in RA but none of the available drugs (tofacitinib, baricitinib, upadacitinib, and filgotinib) have consistently been evaluated in renal amyloidosis (35).